Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial).

Background: Despite the advances introduced by the PACIFIC trial, recurrence after definitive chemoradiotherapy (CRT) followed by durvalumab consolidation remains a significant clinical challenge in unresectable stage III non-small cell lung cancer (NSCLC). This study aims to investigate relapse patterns and outcomes of salvage treatments in a real-world cohort, providing insights for post-progression management.

Methods: We performed a retrospective analysis of 166 patients with unresectable stage III NSCLC treated with the PACIFIC regimen across eight Italian centers from January 2018 to December 2021.

Predicting Complicated Grief in Caregivers of End-of-Life Cancer Patients.

ObjectivesPersistent Complex Bereavement Disorder (PCBD) is an independent clinical condition characterized by a severe grief reaction lasting more than twelve months after the loss of a loved one. This study aimed to assess the rate of PCBD among caregivers of end-of-life patients. The secondary aim was to explore the role of several risk factors for PCBD, including psychosocial characteristics of both patients and caregivers, patients' dignity-related distress, attachment style, and perceived social support as well as symptoms of depression, anxiety, and perceived stress of caregivers.

Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study.

Background: Currently, patients with unresectable stage III non-small-cell lung cancer (NSCLC) ineligible for chemotherapy receive radiotherapy alone, with unsatisfactory results. DUART was a phase II single-arm trial of durvalumab in patients without progression after radiotherapy for unresectable stage III NSCLC.

Patients And Methods: Patients were enrolled into parallel cohorts per radiotherapy dose (A: definitive; B: palliative) and received durvalumab (1500 mg every 4 weeks for up to 12 months).

Lung Stereotactic Body Radiotherapy (SBRT): Challenging Scenarios and New Frontiers.

Stereotactic Body Radiotherapy (SBRT) has emerged as a pivotal treatment modality for early-stage non-small cell lung cancer (NSCLC), offering highly precise, high-dose radiation delivery. However, several clinical challenges remain, particularly in the treatment of central or ultracentral tumors, which are located near critical structures such as the heart, bronchi, and great vessels. The introduction of MRI-guided SBRT has significantly improved targeting precision, allowing for better assessment of tumor motion and adjacent organ structures.

The Role of Radiotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Post-CAR-T Therapy: A Systematic Literature Review.

IntroductionHistorically, the management of relapsed or refractory diffuse large B-cell lymphoma (r/r-DLBCL) involved chemotherapy and autologous stem cell transplant, though outcomes were often suboptimal. Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the therapeutic landscape for r/r-DLBCL, achieving high response rates and improving progression-free and overall survival. However, a significant proportion of patients relapse after CAR-T, and optimal treatment strategies for post-CAR-T relapse remain unclear.